Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
- PMID: 9568710
- DOI: 10.1016/s0092-8674(00)81569-x
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
Abstract
The ligand for osteoprotegerin has been identified, and it is a TNF-related cytokine that replaces the requirement for stromal cells, vitamin D3, and glucocorticoids in the coculture model of in vitro osteoclastogenesis. OPG ligand (OPGL) binds to a unique hematopoeitic progenitor cell that is committed to the osteoclast lineage and stimulates the rapid induction of genes that typify osteoclast development. OPGL directly activates isolated mature osteoclasts in vitro, and short-term administration into normal adult mice results in osteoclast activation associated with systemic hypercalcemia. These data suggest that OPGL is an osteoclast differentiation and activation factor. The effects of OPGL are blocked in vitro and in vivo by OPG, suggesting that OPGL and OPG are key extracellular regulators of osteoclast development.
Similar articles
-
Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.J Cell Biochem. 1999 Feb 1;72(2):251-61. J Cell Biochem. 1999. PMID: 10022507
-
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.J Cell Biol. 1999 May 3;145(3):527-38. doi: 10.1083/jcb.145.3.527. J Cell Biol. 1999. PMID: 10225954 Free PMC article.
-
Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.Am J Pathol. 2000 Mar;156(3):761-7. doi: 10.1016/s0002-9440(10)64942-5. Am J Pathol. 2000. PMID: 10702390 Free PMC article.
-
A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.Biochem Biophys Res Commun. 1999 Mar 24;256(3):449-55. doi: 10.1006/bbrc.1999.0252. Biochem Biophys Res Commun. 1999. PMID: 10080918 Review.
-
Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.Curr Pharm Des. 2001 May;7(8):613-35. doi: 10.2174/1381612013397807. Curr Pharm Des. 2001. PMID: 11375772 Review.
Cited by
-
Unraveling the Intricacies of OPG/RANKL/RANK Biology and Its Implications in Neurological Disorders-A Comprehensive Literature Review.Mol Neurobiol. 2024 May 22. doi: 10.1007/s12035-024-04227-z. Online ahead of print. Mol Neurobiol. 2024. PMID: 38777981 Review.
-
Pleurotus sajor-caju (Fr.) Singer β-1,3-Glucanoligosaccharide (Ps-GOS) Suppresses RANKL-Induced Osteoclast Differentiation and Function in Pre-Osteoclastic RAW 264.7 Cells by Inhibiting the RANK/NFκB/cFOS/NFATc1 Signalling Pathway.Molecules. 2024 May 2;29(9):2113. doi: 10.3390/molecules29092113. Molecules. 2024. PMID: 38731604 Free PMC article.
-
Tissue adaptation of CD4 T lymphocytes in homeostasis and cancer.Front Immunol. 2024 Apr 16;15:1379376. doi: 10.3389/fimmu.2024.1379376. eCollection 2024. Front Immunol. 2024. PMID: 38690280 Free PMC article.
-
Overexpression of TNFSF11 reduces GPX4 levels and increases sensitivity to ferroptosis inducers in lung adenocarcinoma.J Transl Med. 2024 Apr 9;22(1):340. doi: 10.1186/s12967-024-05112-y. J Transl Med. 2024. PMID: 38594779 Free PMC article.
-
Osteoprotegerin in infection-induced acute inflammatory states in children.Heliyon. 2024 Mar 7;10(6):e27565. doi: 10.1016/j.heliyon.2024.e27565. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38509997 Free PMC article.
MeSH terms
Substances
Associated data
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
